| Description | D-Luciferin (D-(-)-Luciferin) is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications. |
| In vitro | D-luciferin与luciferase、ATP和氧气发生反应，并伴随着光的发射。该光线通过敏感的摄影胶片检测，从而允许可视化碱性磷酸酶偶联的抗体。[1] |
| In vivo | 在免疫完整型卵巢癌小鼠模型中，通过使用D-luciferin底物和萤火虫luciferase，可以保持肿瘤-宿主间的免疫互动，因为生物发光成像是比体重增加更敏感的肿瘤生长指标。[2] |
| Synonyms | Firefly luciferin, D-萤光素, D-荧光素, D-(-)-Luciferin |
| molecular weight | 280.32 |
| Molecular formula | C11H8N2O3S2 |
| CAS | 2591-17-5 |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | Ethanol: 1 mg/mL (3.56 mM) DMSO: 55 mg/mL (196.2 mM) |
| References | 1. Hauber R, et al. J Clin Chem Clin Biochem. 1987, 25(8), 511-514. 2. Liao JB, et al. J Immunother Cancer. 2015. doi: 10.1186/s40425-2015-20060-6. |
| Citations | 1. Liang Q, Hu Y, Yuan Q, et al.MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.British Journal of Cancer.2023: 1-14. 2. Yao H, Huang C, Zou J, et al.Extracellular vesicle‐packaged lncRNA from cancer‐associated fibroblasts promotes immune evasion by downregulating HLA‐A in pancreatic cancer.Journal of Extracellular Vesicles.2024, 13(7): e12484. |